Core-Shell mRNA Vaccine Platform for RNase Protection and APC Uptake
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing mRNA-based cancer vaccines face challenges such as mRNA degradation, exposure to immune cells leading to adverse reactions, and inefficient internalization by antigen-presenting cells, limiting their effectiveness in stimulating robust anti-tumoral immunity.
Innovation Solution
A biocompatible core/shell composition is developed, where mRNA is encapsulated in a positively-charged polymer core within a hydrophilic lipid bilayer shell, protecting the mRNA from degradation and enhancing uptake by antigen-presenting cells like dendritic cells, thereby stimulating potent anti-tumoral immunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mRNA is delivered naked or with simple condensing agents, then the vaccine can be produced and administered, but the mRNA is vulnerable to degradation by plasma and tissue RNases
Solution Approach 1:
The mRNA is nested within a polyplex core structure formed by condensing agents, which is then further encapsulated within a lipid nanoparticle shell. This multi-layer nesting provides progressive protection against RNase degradation while maintaining delivery efficiency
Solution Approach 2:
The vaccine combines multiple materials with complementary properties: cationic polymers or lipids for mRNA condensation, neutral or anionic lipids for structural stability, and PEGylated lipids for steric protection. This composite approach creates a robust delivery system that resists enzymatic degradation
2Ease of operation
If mRNA is packaged with protamine to enable cellular uptake and stimulate TLR signaling, then antigen-presenting cell uptake is improved, but naked mRNA exposure to body fluid increases vulnerability to RNases
Solution Approach 1:
The protamine-condensed mRNA core is nested within an additional lipid nanoparticle shell. This outer shell reduces naked mRNA exposure to body fluids and RNases while preserving the protamine's ability to facilitate cellular uptake and TLR signaling
Solution Approach 2:
The lipid nanoparticle shell provides localized protection at the surface of the vaccine particle, allowing the protamine-condensed core to maintain its immunostimulatory functions while the shell barrier prevents RNase access to the mRNA
3Reliability
If mRNA vaccine is prepared by transfecting into patient-derived dendritic cells by electroporation, then antigen presentation can occur, but mass production of off-the-shelf therapeutic vaccines is not enabled
Solution Approach 1:
The lipid nanoparticle formulation enables the mRNA vaccine to be self-administerable through simple injection without requiring electroporation or other complex ex vivo processing steps. This simplifies manufacturing and enables off-the-shelf therapeutic vaccine production
Solution Approach 2:
The complex mechanical electroporation process is replaced with a simple injection-based delivery system using biodegradable lipid nanoparticles, dramatically simplifying the manufacturing process while maintaining efficacy
4Adaptability or versatility
If mRNA molecules are exposed to non-antigen-presenting cells, then the vaccine can be distributed systemically, but there is a risk of triggering adverse reactions inside the body
Solution Approach 1:
The surface properties of the mRNA complex are modified by PEGylation and lipid composition adjustments, changing the physical and chemical parameters to reduce immunogenicity and prevent adverse reactions while maintaining systemic distribution capability
Solution Approach 2:
The lipid nanoparticle shell acts as an intermediary between the mRNA and the immune system, allowing systemic distribution while filtering out harmful interactions with non-target cells
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The core/shell structure significantly enhances the potency of mRNA vaccines by protecting mRNA from degradation and improving cellular uptake, leading to increased expression of interferon-β, interferon-α, and interleukin-12, and robust anti-tumor immune responses.
Implementation Method 1
mRNA is encapsulated in a positively-charged polymer core
Implementation Method 2
encapsulated with an outer hydrophilic lipid bilayer-containing shell
Data Source
AI summary
Disclosed are biocompatible core/shell compositions suitable for the delivery of populations of mRNA molecules to mammalian cells. The disclosed core-shell structured multicomponent compositions are optimized for the delivery of mRNAs encoding one or more cancer- or tumor-specific antigens to a population of antigen presenting cells, including, for example, human dendritic cells, macrophages and B cells. Also disclosed are methods for use of these compositions as therapeutic cancer vaccines.